Protagonist Therapeutics
PTGX
121.40
-2.62
-2.11%
Protagonist Therapeutics
US · PTGX
#1570 by market cap
Listed 2016
121.40
-2.62
-2.11%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Protagonist Therapeutics
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
- Founded
- 2006
- CEO
- Dr. Dinesh V. Patel, PhD
- Employees
- 132
- Headquarters
- Newark, California, United States of America
- Fiscal year end
- 12-31
- Website
- protagonist-inc.com
Company profile
- Exchange
- US
- Symbol
- PTGX
- Market-cap rank
- #1570
- Listing date
- 2016-08-11
- Market cap
- 7.92B
- Float cap
- 6.48B
- Shares out
- 65.27M
- Float shares
- 53.36M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Protagonist Therapeutics discussion 0 comments